CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The complex role of IL-10 in malignant ascites: a review.
The complex role of IL-10 in malignant ascites: a review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
恶性腹水（MA）的出现提示卵巢癌、胃肠道癌、乳腺癌和胰腺癌患者预后不良。白细胞介素-10（IL-10）是一种多效性细胞因子，在肿瘤微环境中具有免疫调节作用。MA中IL-10的水平因癌症类型和患者而异，影响癌症进展和结局。IL-10来源于多种免疫细胞和癌细胞，在MA中参与复杂的信号通路。全身性给予IL-10，尽管其治疗MA疗效的证据有限，但仍作为一种有前景的治疗策略出现，因为它可以直接增强CD8+ T细胞的细胞毒性并激活耗竭的CD8+TIL（肿瘤浸润淋巴细胞）（TILs）。IL-10信号阻断在MA治疗中与其他免疫疗法联合也展现出巨大潜力。我们综述了恶性腹水中IL-10的水平、来源和功能，并概述了当前靶向IL-10信号的治疗方法，旨在为MA治疗提供见解。
The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA.
Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment.
We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
